Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-risk Acute Myeloid Leukemia: A Single Center Experience

Tremendous progress in our understanding of the biology of acute myeloid leukemia (AML) has yet to be translated into improved patient outcomes, as evidenced by a 5-yr survival rate of only 30%. This dismal outcome is driven by certain subgroups of AML patients, informally referred to as high-risk AML, characterized by advanced age, poor risk cytogenetics, and secondary AML (s-AML), therapy-related AML (t-AML), or AML with myelodysplastic related changes (AML-MRC). It is well recognized that AML patients with an adverse cytogenetic profile have worse survival than those with favorable or intermediate risk cytogenetic profiles[1,2].

Source: Leukemia Research - October 25, 2018 Category: Hematology Authors: Pankit Vachhani, Raed Al Yacoub, Austin Miller, Fan Zhang, Tara L. Cronin, Evelena P. Ontiveros, James E. Thompson, Elizabeth A. Griffiths, Eunice S. Wang Tags: Research paper Source Type: research